Charles Makin MS, MBA

Charles Makin plays a dual role at Biogen, serving as both the Global Head of the HEOR, HTA, and RWE team; and the Global Head of Value & Access for Biogen’s pipeline franchise. As the leader of the HEOR, HTA & RWE team, Charles leads the design, generation, and application of innovative RWE and outcomes research spanning both prospective and retrospective methodologies; and leads the development of economic models to create compelling and quantitative value propositions. As the head of the pipeline team, he ensures that market access and HEOR strategies are progressively being incorporated earlier into the drug development phases, helping further align Biogen’s regulatory and clinical evidence strategies with the reimbursement strategy.

Before joining Biogen, Mr. Makin served as the General Manager/Vice President for ICON’s RWE-Late Phase Research unit, comprised of several hundred biostatisticians, medical affairs personnel, project/program managers, and data management professionals based in >40 countries – to the 2018 Late-Phase CRO Leadership Award. Prior to that, he held leadership positions in major drug commercialization research companies such as IQVIA and Optum, and prior to that, he worked for large payers such as Anthem and Humana.